| abstract |
The present invention relates to compounds of formula I useful for the treatment of hepatitis C virus (HCV) infection. In this compound, the uracil or thymine derivative is linked to a 2-ring cyclic system (R6) fused via phenylene or alternatively through a further 2-atom linker (L) to a 5- to 6-membered monocycle Lt; / RTI > The present application is also related to the preparation of two specific compounds, namely N- (6- (3- tert -butyl-5- (2,4-dioxo-3,4-dihydropyrimidin- (E) -N- (4- (3-tert-butyl-5- (2,4-dioxo-3,4-dihydropyrimidin- (2H) -yl) -2-methoxystyryl) phenyl) methanesulfonamide as well as pseudopolymorphs. |